Doomsday Clock is closest its ever been to human extinction, but University of Chicago scientists remain optimistic
It was a small change, but a frightening one. Last month, the "Doomsday Clock" was moved up to 89 seconds, the closest the world has ever been to total annihilation.
The Bulletin of Atomic Scientists, based at the University of Chicago, uses the clock as a metaphor to show how close the planet is to reaching human extinction.
Believe it or not, the goal of the Doomsday Clock isn't to scare you. It's to make you take action.
Despite the grim message the clock currently conveys, one of the people behind it is actually optimistic about humanity's future.
University of Chicago professor Daniel Holz is one of the people who moved the Doomsday Clock forward last month. He's the current chair of the Science and Security Board at the Bulletin of Atomic Scientists, which has been tracking the risk of world destruction since atomic weapons were invented.
"It's a symbolic thing. We're trying to capture the urgency of the moment," he said. "We're at a moment of incredible danger. Everyone is freaked out. What are we doing? We need to turn the clock back."
At this moment, Holz said humanity is threatened by nuclear weapons…
"We're building more weapons, we're modernizing the arsenal. Even though we have plenty of weapons to wipe out civilization many times over ... we want even more and even better weapons. You can ask why, but we're doing it, China's doing it, Russia is doing it, the treaties are all going away," he said.
Climate change...
"Climate change is happening. We just came off the hottest year on record. There are fires, there was floods, there's extreme drought. There are extreme storms. It's all happening. I don't think anyone paying any attention has any doubt at this point that climate change is happening, and it's getting worse," Holz said.
Biohazards like pandemics...
"Because of travel, because of modern life as we know it, pandemics have a tendency to go much faster, and we saw that with COVID, and no place is safe," Holz said.
And even artificial intelligence...
"If an AI hallucinates and ends civilization, that would be a bummer," Holz said.
But the clock isn't meant to depress you. It's designed to inspire you.
"We're hoping that, by bringing attention to this, people will react accordingly, and the clock will be turned back," Holz said.
The clock did turn back in 2010.
So, what would make Holz and the Bulletin move the clock in the right direction again?
"Heads of state saying, 'Whoa, we do have to talk. Let's not just demonize each other, but let's sit down and try to make a deal. Let's try to work something out.' That is progress," he said.
Holz said there are already positive signs on climate change.
"The world is increasingly aware; and citizens, people on the streets are increasingly aware. We need that to kind of trickle up, as it were, to leadership," Holz said. "To be on this board to work with the Doomsday Clock is a fundamentally optimistic endeavor. If we were convinced it was hopeless, there's no point in spending one's time doing this."
The furthest from midnight the Doomsday Clock has ever been was 17 minutes to midnight in 1991, after the Cold War ended and a new arms treaty between the U.S. and the Soviet Union greatly reduced the number of nuclear weapons in their arsenals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
This Poop 'Cure' May Have Unintended Long-Term Effects, Study Finds
Faecal microbial transplants (FMT), which involve transferring stool samples from a healthy gut to someone else's colon, have yielded some impressive medical results in the past. Researchers have seen promising signs of its ability to address irritable bowel syndrome, Crohn's disease, and even early Parkinson's (though this benefit only seemed to be short-lived) and other neurological issues. It has a 90% success rate for treating a bacterium related to diarrhoea, the BBC reported. But a new study published in the journal Cells has raised questions about the long-term safety of FMT treatments, suggesting that a bacterial 'mismatch' may cause problems with the patient's immune system and metabolism down the line. The scientists only found the link in mice and were not able to say how the changes they witnessed in the animals might manifest in people. They gave antibiotics to mice to interrupt their gut's normal microbiome, and then treated them with FMT and monitored them for one to three months. Often, the researchers discovered, the gut bacteria ended up in the wrong part of the gut – 'regional mismatches' – that seemed to disrupt the gut. After taking biopsies of the liver and gut, the scientists found that some genes, especially those related to the immune system and metabolism, had changed. Speaking to the University of Chicago, the study's lead author, researcher Orlando 'Landon' DeLeon said: 'I think it's a bit of a wake-up call to the field that maybe we shouldn't willy-nilly put large bowel microbes into different parts of the intestine that shouldn't be there. 'There are microbes along the entire intestinal tract, and we just study predominantly the last third of it (the colon),' he added. 'So how can you expect an FMT, with microbes from a third of the intestinal tract at the end of it, to fix the rest of the intestine?' No. This study was done on mice, which have different anatomies from us; even though the scientists found genetic changes in the liver and gut, they are not sure yet how those changes might affect even the mouse, never mind us. The study's researchers, however, still think it's a good idea to pursue 'omni-microbial transplants,' or OMT, writing in their paper: 'regional microbial mismatches after FMTs can lead to unintended consequences and require rethinking of microbiome-based interventions.' OMTs would include more bacteria from a greater area of the gut, theoretically increasing the likelihood that the correct ones will go to the right spot. Gut Health Discovery Could Help Future Parkinson's Diagnoses Let's Settle This – Is The Viral 'Puff Vs Pit' Armpit Health Check Actually Helpful? New Study Finds The Exact Age Bad Health Habits Catch Up To You
4 days ago
What to know about COVID variant NB.1.8.1 causing 'razor blade throat'
A newer COVID-19 variant may be causing a severe sore throat in some people who contract the infection. The variant, known as NB.1.8.1, has been nicknamed by some as "razor blade throat" due to the painful symptom. Data from the open global genome sequencing database GISAID shows the new variant has been detected in several states, including New York, Illinois, Texas and California. Public health experts told ABC News there is no cause for serious concern yet because the virus does not appear to be more severe than previous variants and there are steps that can be taken to protect yourself. What is NB 1.8.1? NB.1.8.1 derives from the recombinant variant XVD.1.5.1, which is a descendant of the omicron variant. The first sample of NB.1.8.1 was collected on Jan. 22, according to the World Health Organization (WHO). It was first detected in China and other parts of Asia before spreading to Europe. It was designated as a "variant under monitoring" by the WHO, meaning it may require prioritized attention and monitoring but is not as serious as a "variant of interest" or a "variant of concern." As of the week ending June 7, NB.1.8.1 is the second most dominant variant in the U.S., accounting for an estimated 37% of cases, according to the Centers for Disease Control and Prevention (CDC). The virus appears to be more transmissible because there appear to be changes to the spike protein, which is what the virus uses to attach to and infect cells, said Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco. It also seems to attach more easily to ACE2 receptors, which are proteins found on the surface of cells and how the virus that causes COVID enters cells, he told ABC News. NB.1.8.1 doesn't yet appear to be causing increases in cases or in hospitalizations with rates remaining "stable" so far, according to Chin-Hong. The variant has also been called "Nimbus," which appears to have been coined on X by T. Ryan Gregory, a Canadian professor of evolutionary biology. "Nimbus is a catchy, quick name, and it also includes an 'N' and a 'B' from the lineage, which is NB.1.8.1. So it's easier for people to be able to say these monikers for COVID, rather than remember the actual lineage," said Dr. Alok Potel, a pediatrician at Stanford Children's Health and an ABC News contributor. "But I think it's important also because it keeps people paying attention to new COVID variants that can be different in terms of infectivity and in terms of spread," he added. What are the symptoms? Experts said they are not sure if the painful sore throat is just a symptom that people are talking about or a distinctive symptom of this variant. It's also unclear if the "razor blade throat" is more common in those who are more up to date on vaccination compared to those who are not up to date. "I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum," Chin-Hong said. There is currently no evidence that NB.1.8.1. causes more severe disease or is more likely to cause hospitalization, according to Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center in Nashville, "But of course, there are people in high-risk groups that are still at risk of being hospitalized should they become infected," he told ABC News. There are no other symptoms outlined that are specific to NB.1.8.1 by the CDC. Symptoms listed by the health agency still include sore throat, cough, fever, chills, shortness of breath, difficulty breathing, congestion, runny nose, loss of taste or smell, fatigue, muscle aches, body aches, headache, nausea, vomiting or diarrhea. How to protect yourself The experts recommend that high-risk Americans receive a vaccine twice a year as recommended by the CDC. The CDC also currently recommends most adults aged 18 and older receive an updated 2024-2025 vaccine and that parents of children between ages 6 months to 17 years discuss the benefits of vaccination with a health care provider. COVID-19 also tends to spike in the late summer and early fall, so people should consider opening windows to increase ventilation, wearing a mask in certain situations and avoiding crowded areas, Schaffner said. "Time to stream a movie, as I like to say, rather than going to the movies," he added. Patel said it's important to practice good hygiene such as proper hand-washing and covering your mouth when coughing or sneezing. He also recommended that people test if they are symptomatic and said over-the-counter rapid at-home tests work. "Getting infected with COVID and other infectious diseases is not necessarily life or death, but it can still be very debilitating." Patel said. "It can cause people to miss work, to spread the virus, to get people who are higher risk sick and there's still an untold amount of people who have long COVID." He added, "So, we don't want to look at COVID as just another common cold, because there's still so much we're learning about it, and there's still so many possibilities with this virus continuing to mutate, if we let it."
Boston Globe
4 days ago
- Boston Globe
For Boston's budding biotechs, an uncertain future amid funding cuts
Early stage startups, operating without much financial cushion, are feeling the impact sooner than better-established companies. Advertisement Dépis, and many entrepreneurs like him, are looking for ways to get their science funded. For example, LabCentral, a biotech startup incubator, has a program that allows big pharmaceutical companies to invest in cutting-edge science without making long-term commitments. Pharma companies cover the costs of lab space for individual scientists for a year, providing an easy exit if the research doesn't prove promising. In its recent five-year strategic plan, the Massachusetts Biotechnology Council pitched the idea of a seed fund to support companies that graduate from the trade group's incubator program. Discussions are underway with MassBio's partners such as LabCentral and the Massachusetts Life Sciences Center, a quasi-public state agency. Advertisement 'What's happened this year just validated our plans,' said MassBio CEO Kendalle Burlin O'Connell. 'We knew that we needed to support these early stage companies. We really, really feel it's imperative for Massachusetts to be an entrepreneur, founder-centric ecosystem.' Dépis — who is researching techniques to better deliver drugs to treat immune diseases — says such support is sorely needed. Earlier this year, he applied for a federal Small Business Innovation Research grant; then the government employee responsible for his application was laid off. Two weeks later, the employee was reinstated, but Dépis's application remains in limbo. 'I'm in a position where time is critical,' Dépis said. 'For me that translates into a higher chance to not have the funding in time that I need to survive.' And Dépis is not alone. Before the post-COVID biotech slump, companies accepted at LabCentral could typically secure funding and move into the space in a few weeks. Now, startups are taking six months to a year to move in — if they move in at all, said LabCentral CEO Maggie O'Toole. Startups at LabCentral are staying longer, unable to raise the money needed to grow their companies and expand into their own facilities, O'Toole said. The average length of tenancy doubled to about 36 months from 18 months, Some startups, affected by the Trump administration's grant cuts, have had to give up their LabCentral benches because they can't pay the rent. 'It was nothing to do with the promise of their science,' O'Toole said. 'They had received [approval for] funding that never came through.' Advertisement Robert Coughlin, a managing director at the commercial real estate firm JLL and former MassBio CEO, said the biotech industry is going through a downturn reminiscent of the Great Recession of 2008. Layoffs have spread across the sector. Earlier this month, Boston-based Vertex Pharmaceuticals said it would Moderna, the Cambridge biotech that soared with the success of its COVID vaccine, has gone through recent layoffs. In 2024, employment across Massachusetts' life sciences sector stagnated for the first time in more than 10 years, according to a report from the Massachusetts Biotechnology Education Foundation. Boston's commercial real estate sector has been hurt by the biotech slump. The vacancy rate for lab space has reached 32 percent, the highest among major metropolitan areas, according to JLL's most recent US Life Sciences Property Report. While conditions seem dismal, Coughlin said, he noticed a sense of optimism at the BIO conference. The annual convention not only attracted big crowds from established biotech centers, but also representatives from states and countries looking to invest in and build their own life sciences sectors. 'People want to get together,' Coughlin said. 'They want to collaborate, they want to talk about these challenges.' Marin Wolf can be reached at
